Tag: Urban Outfitters

  • Dex One Jumps On Acquisition News (DEXO, URBN, NDSN, PRAN, PSTI)

    Dex One Corporation (NYSE:DEXO) among the gainers and the stock surged up 48.39% to $1.84. Dex One Corporation and SuperMedia Inc have agreed to merge. The Boards of Directors of both the Companies have approved a definitive agreement under which Dex One and SuperMedia will combine in a stock-for-stock merger of equals. This merger will create a national provider of social, local and mobile marketing solutions through direct relationships with local businesses. Dex One shareholders are expected to own approximately 60% and SuperMedia shareholders are expected to own approximately 40% of the combined company.

    Urban Outfitters Inc (NASDAQ:URBN) augmented 15.63% to $6.19 on a traded volume of 1.28 million shares after the Company released second quarter results. Net income was $61.3 million or 42 cents per share compared to $56.7 million or 35 cents in the prior year period. However, analysts’ average estimate was 33 cents per share. Second-quarter net sales increased 11% to $676.3 million. The increase in sales was driven by the namesake, Anthropologie and Free People brands.

    Nordson Corporation (NASDAQ:NDSN) is one of the top movers and the stock soared 11.11% to $61.11 after the Company reported third quarter results. Net sales increased 21.7% to $379.9 million. However, analysts on a consensus estimated revenues of $358.45 million. Net income was $66.7 million or $1.03 per share compared to $56.6 million or $0.82 per share in the prior year period.

    Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) increased 5.01% to $1.83. The stock opened at $1.85. So far, the stock went up 24%. The 52-week range of the stock $1.98 and $5.0.

    Pluristem Therapeutics Inc (NASDAQ:PSTI) climbed up 2.50% to $4.10. The Company has received permission from the Indian Ministry of Health to proceed with a Phase II clinical trial for the treatment of thromboangiitis obliterans. This Phase II trial will be potentially followed by a multi-national Phase III study in the U.S., Europe and India.